{"id":"W4200333351","doi":"10.1016/s1470-2045(25)00522-4","title":"Correction to Lancet Oncol 2024; 25: 1038–52","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Grail; Program for Creating STart-ups from Advanced Research and Technology; UCLH Biomedical Research Centre; Novartis; Merck Sharp and Dohme; American Association for Cancer Research; Servier; Basilea Pharmaceutica; Medical Research Council; Celgene; Johnson and Johnson; AstraZeneca; Genentech; Ipsen; Vifor Pharma; PharmaMar; Deutsche Krebshilfe; Bayer; Astellas Pharma; MedImmune; Daiichi-Sankyo; National Institutes of Health; CRUK Lung Cancer Centre of Excellence; Rosetrees Trust; Cancer Research UK; Janssen Pharmaceuticals; Breast Cancer Research Foundation; Canadian Cancer Society; Center for Cancer Research; National Institute for Health and Care Research; Clovis Oncology; Astex Pharmaceuticals; Harvard University; Entertainment Industry Foundation; AbbVie; National Cancer Institute; Gilead Sciences; Pfizer; Baxter International; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; American Society of Clinical Oncology; Bristol-Myers Squibb; Deutsche Forschungsgemeinschaft; Roche; Astellas Pharma US","keywords":"Medicine; Family medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007938043,0.003391806,0.003824943,0.004474504,0.00315259,0.008085573,0.004286303,0.01962441,0.1045188],"category_scores_gemma":[0.08315608,0.001782095,0.003574837,0.002531708,0.00309265,0.003071527,0.003310334,0.02618961,0.07031129],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005857034,"about_ca_system_score_gemma":0.00867239,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01271931,"about_ca_topic_score_gemma":0.01774353,"domain_scores_codex":[0.9916252,0.001602821,0.001004728,0.001085188,0.003476922,0.00120511],"domain_scores_gemma":[0.9557072,0.01434809,0.003100337,0.002850746,0.01926849,0.004725123],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001637355,0.000002010838,0.00001364539,0.00007287073,0.000009299173,0.00002891223,0.000005001728,0.00001193245,0.000008900793,0.0002074645,0.9977724,0.001851081],"study_design_scores_gemma":[0.00009915014,0.00001393638,0.0001974277,0.0003823808,0.00004585782,0.00009977115,0.00002045979,0.00006692647,0.00004856669,0.0009526546,0.9980505,0.000022411],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.00001768233,0.00173962,0.0001405083,0.06718129,0.9286129,0.00001405456,0.0004504149,0.0001357618,0.001707771],"genre_scores_gemma":[0.001942352,0.007356091,0.0007934462,0.2235489,0.6803234,0.0002180956,0.0009744517,0.0005543391,0.0842889],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.1045188,"threshold_uncertainty_score":0.3496502,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04504243712373093,"score_gpt":0.3746384579841051,"score_spread":0.3295960208603741,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}